Skip to Main Content

Author Details

Shirley V Wang
Brigham and Women's Hospital, Harvard Medical School
2009
90
25
PMIDPaper TitleJournal TitlePublished Year
37853843High-Dose vs. Standard-Dose Influenza Vaccine and Cardiopulmonary Hospitalization or Mortality: Emulating the INVESTED Trial Using Insurance Claims Data.Clin Pharmacol Ther2024
36215113HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force.Pharmacoepidemiol Drug Saf2023
37597260Comparison of EHR Data-Completeness in Patients with Different Types of Medical Insurance Coverage in the United States.Clin Pharmacol Ther2023
37549393Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease.Ann Intern Med2023
37502999DESIGN DIFFERENCES EXPLAIN VARIATION IN RESULTS BETWEEN RANDOMIZED TRIALS AND THEIR NON-RANDOMIZED EMULATIONS.medRxiv2023
37606676Understanding the Facets of Emulating Randomized Clinical Trials-Reply.JAMA2023
37340238Use of Electronic Health Record Data for Drug Safety Signal Identification: A Scoping Review.Drug Saf2023
37365904Predicting Treatment Effects of a New-to-Market Drug in Clinical Practice Based on Phase III Randomized Trial Results.Clin Pharmacol Ther2023
37097356Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses: Results of 32 Clinical Trials.JAMA2023
37026443The Impact of Longitudinal Data-Completeness of Electronic Health Record Data on the Prediction Performance of Clinical Risk Scores.Clin Pharmacol Ther2023
36408668The Aetion Coalition to Advance Real-World Evidence through Randomized Controlled Trial Emulation Initiative: Oncology.Clin Pharmacol Ther2023
36464785Prospective validation of a dynamic prognostic model for identifying COVID-19 patients at high risk of rapid deterioration.Pharmacoepidemiol Drug Saf2023
34416020Assessing and Interpreting Real-World Evidence Studies: Introductory Points for New Reviewers.Clin Pharmacol Ther2022
35520277A Framework for Visualizing Study Designs and Data Observability in Electronic Health Record Data.Clin Epidemiol2022
36075314Understanding variation in the results of real-world evidence studies that seem to address the same question.J Clin Epidemiol2022
35868493Gastrointestinal prophylaxis for COVID-19: an illustration of severe bias arising from inappropriate comparators in observational studies.J Clin Epidemiol2022
36241338HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force.Value Health2022
35984046Visualizations throughout pharmacoepidemiology study planning, implementation, and reporting.Pharmacoepidemiol Drug Saf2022
35947646Real-World Evidence Prediction of a Phase IV Oncology Trial: Comparative Degarelix vs Leuprolide Safety.JNCI Cancer Spectr2022
35092316Transparency of high-dimensional propensity score analyses: Guidance for diagnostics and reporting.Pharmacoepidemiol Drug Saf2022
32777229Screening Medications for Association with Progression to Wet Age-Related Macular Degeneration.Ophthalmology2021
33715267Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology.Pharmacoepidemiol Drug Saf2021
33615330A General Propensity Score for Signal Identification Using Tree-Based Scan Statistics.Am J Epidemiol2021
33834577Online tool to create publication ready graphical depictions of longitudinal study design implemented in healthcare databases.Pharmacoepidemiol Drug Saf2021
34931012Broadening the reach of the FDA Sentinel system: A roadmap for integrating electronic health record data in a causal analysis framework.NPJ Digit Med2021
34277962A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes.Endocrinol Diabetes Metab2021
33436424STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies.BMJ2021
33423046Active Surveillance of the Safety of Medications Used During Pregnancy.Am J Epidemiol2021
31569120Use of Time-Dependent Propensity Scores to Adjust Hazard Ratio Estimates in Cohort Studies with Differential Depletion of Susceptibles.Epidemiology2020
31922560Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.JAMA Netw Open2020
32105168Application of a Graphical Depiction of Longitudinal Study Designs to Managed Care Pharmacy Research.J Manag Care Spec Pharm2020
32639512Using the Case-Crossover Design to Assess Short-Term Risks of Bleeding and Arterial Thromboembolism After Switching Between Oral Anticoagulants in a Population-Based Cohort of Patients With Atrial Fibrillation.Am J Epidemiol2020
32606986Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model.Clin Epidemiol2020
32940229Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.Value Health2020
32924243Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.Pharmacoepidemiol Drug Saf2020
32613596Determining Which of Several Simultaneously Administered Vaccines Increase Risk of an Adverse Event.Drug Saf2020
32250527Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes.Diabetes Obes Metab2020
32113627Comparison of Different Case-Crossover Variants in Handling Exposure-Time Trend or Persistent-User Bias: Using Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure as an Example.Value Health2020
32548875Bias in case-crossover studies of medications due to persistent use: A simulation study.Pharmacoepidemiol Drug Saf2020
31020732Evaluating the use of bootstrapping in cohort studies conducted with 1:1 propensity score matching-A plasmode simulation study.Pharmacoepidemiol Drug Saf2019
30107034Using Real-World Data to Extrapolate Evidence From Randomized Controlled Trials.Clin Pharmacol Ther2019
31243156Stepped-wedge randomised trial to evaluate population health intervention designed to increase appropriate anticoagulation in patients with atrial fibrillation.BMJ Qual Saf2019
31452075Transparent Reporting on Research Using Unstructured Electronic Health Record Data to Generate 'Real World' Evidence of Comparative Effectiveness and Safety.Drug Saf2019
31038730Using Healthcare Databases to Refine Understanding of Exploratory Associations Between Drugs and Progression of Open-Angle Glaucoma.Clin Pharmacol Ther2019
30856654Graphical Depiction of Longitudinal Study Designs in Health Care Databases.Ann Intern Med2019
31111340Evaluation of Use of Technologies to Facilitate Medical Chart Review.Drug Saf2019
30873670Commentary in response to Carrigan et al: "An Evaluation of the Impact of Missing Deaths on Overall Survival Analyses of Advanced Non-small Cell Lung Cancer Patients Conducted in an Electronic Health Records Database".Pharmacoepidemiol Drug Saf2019
29318683Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System.Pharmacoepidemiol Drug Saf2018
29862551Identifying signals of interest when screening for drug-outcome associations in health care data.Br J Clin Pharmacol2018
30156128Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data.J Comp Eff Res2018
  • 1 - 50 of 90

Recommended Authors

Clair Blacketer
Erasmus University Medical Center
Career Start Year 2016
Number of shared co-authors 3
Yong Chen
the Perelman School of Medicine, University of Pennsylvania
Career Start Year 2015
Number of shared co-authors 1
Jenna M Reps
Erasmus University Medical Center
Career Start Year 2014
Number of shared co-authors 6
Erica A Voss
Erasmus University Medical Center
Career Start Year 2014
Number of shared co-authors 3
Xiaoxi Yao
Department of Cardiovascular Medicine Mayo Clinic Rochester MN.
Career Start Year 2014
Number of shared co-authors 0
Lana Y H Lai
The University of Manchester, University of Manchester
Career Start Year 2013
Number of shared co-authors 3
Ruijun Chen
USA Tempus Labs Inc.
Career Start Year 2012
Number of shared co-authors 3
Nicholas S Downing
Center for Outcomes Research and Evaluation, Yale-New Haven Hospital
Career Start Year 2012
Number of shared co-authors 1
Frank DeFalco
Janssen Pharmaceutical Research & Development
Career Start Year 2011
Number of shared co-authors 5
James Weaver
Janssen Pharmaceutical Research & Development
Career Start Year 2011
Number of shared co-authors 6
Christian Reich
OHDSI Center at The Roux Institute, Northeastern University
Career Start Year 2010
Number of shared co-authors 10
Patrick B Ryan
Columbia University Irving Medical Center
Career Start Year 2010
Number of shared co-authors 14
Orestis A Panagiotou
Department of Health Services, Brown University School of Public Health
Career Start Year 2010
Number of shared co-authors 0
Azza Shoaibi
Janssen Pharmaceutical Research and Development
Career Start Year 2010
Number of shared co-authors 5
Sanket S Dhruva
University of California san francisco
Career Start Year 2008
Number of shared co-authors 3
Kristian Thorlund
McMaster University
Career Start Year 2007
Number of shared co-authors 1
Christine Y Lu
Harvard Medical School and the Harvard Pilgrim Health Care Institute
Career Start Year 2004
Number of shared co-authors 4
Robert A Greevy
Vanderbilt University Medical Center
Career Start Year 2004
Number of shared co-authors 2
Qingxia Chen
Vanderbilt University Medical Center
Career Start Year 2002
Number of shared co-authors 2
Michele Jonsson Funk
University of North Carolina at Chapel Hill
Career Start Year 2002
Number of shared co-authors 0
Nilay D Shah
Mayo Clinic
Career Start Year 2002
Number of shared co-authors 1
Soko Setoguchi
Rutgers University Institute for Health, the State University of New Jersey
Career Start Year 2001
Number of shared co-authors 5
Martijn J Schuemie
University of California los angeles
Career Start Year 2001
Number of shared co-authors 10
Joseph S Ross
Yale School of Medicine
Career Start Year 1999
Number of shared co-authors 5
Jonathan S Schildcrout
Vanderbilt University Medical Center.
Career Start Year 1997
Number of shared co-authors 3
Emily Beth Devine
University of Washington
Career Start Year 1997
Number of shared co-authors 1
Manisha Desai
Stanford University
Career Start Year 1997
Number of shared co-authors 4
John P A Ioannidis
Stanford University
Career Start Year 1994
Number of shared co-authors 2
Til St??rmer
University of North Carolina at Chapel Hill
Career Start Year 1988
Number of shared co-authors 8
Mark G Weiner
Weill Cornell Medical College
Career Start Year 1987
Number of shared co-authors 10

Collaborators

Sebastian Schneeweiss
Division of Pharmacoepidemiology, Brigham & Women's Hospital, Harvard Medical School
Co-authored papers 47
Joshua J Gagne
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital
Co-authored papers 42
Rishi J Desai
Harvard Medical School
Co-authored papers 14
Elisabetta Patorno
Harvard Medical School
Co-authored papers 11
Sengwee Toh
Harvard Medical School and Harvard Pilgrim Health Care Institute
Co-authored papers 9
Michael Nguyen
Center for Drug Evaluation and Research
Co-authored papers 8
Jeremy A Rassen
Brigham and Women's Hospital, Harvard Medical School
Co-authored papers 7
Judith C Maro
Harvard Pilgrim Health Care Institute and Harvard Medical School
Co-authored papers 6
Jeffrey S Brown
Harvard Medical School and Harvard Pilgrim Health Care Institute
Co-authored papers 6
James R Rogers
Columbia University
Co-authored papers 4
Elizabeth A Chrischilles
University of Iowa, School of Public Health
Co-authored papers 4
Nicole L Pratt
Quality Use of Medicines and Pharmacy Research Centre, University of South Australia
Co-authored papers 3
Miriam C J M Sturkenboom
University Medical Center Utrecht
Co-authored papers 3
Olaf H Klungel
Co-authored papers 3
David Madigan
Columbia University.
Co-authored papers 2
Robert Ball
Center for Drug Evaluation and Research
Co-authored papers 2
Gerald J Dal Pan
Center for Drug Evaluation and Research
Co-authored papers 2
Jennifer C Nelson
Kaiser Permanente Washington Health Research Institute
Co-authored papers 2
Aaron S Kesselheim
Brigham and Women's Hospital.
Co-authored papers 2
Adam Wright
Vanderbilt University Medical Center
Co-authored papers 2
Seanna Vine
Co-authored papers 1
Alexander M Walker
Harvard T.H. Chan School of Public Health
Co-authored papers 1
David Moher
University of Ottawa
Co-authored papers 1
Justin Bohn
Harvard Medical School and Harvard Pilgrim Health Care Institute
Co-authored papers 1
Olga V Patterson
University of Utah
Co-authored papers 1
Sharon E Davis
Vanderbilt University Medical Center
Co-authored papers 1
William G Dixon
The University of Manchester
Co-authored papers 1
Lesley H Curtis
Duke Clinical Research Institute
Co-authored papers 1
David W Bates
Brigham and Women's Hospital Division of General Internal Medicine
Co-authored papers 1
David W Bates
Harvard Medical School
Co-authored papers 1
Release 1.2